Vexabax-Sonke
Vexabax-sonke

Vexabax

VEXABAX is a combination of two nucleoside analogues (abacavir and lamivudine). It is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents from 12 years of age, weighing at least 40 kg.

  • Reg. No. : 54/20.2.8/0219
  • Schedule 4
  • Each tablet contains Abacavir Sulphate 600 mg and Lamivudine 300 mg.
  • Dosage: One tablet once a day. 

Telatri

Telatri is indicated for the treatment of HIV-1 infection in adults aged 18 years and older.

  • Reg. No. A47/20.2.8/0483.
  • Schedule 4
  • Each tablet contains Tenofovir 300 mg, Lamivudine 300 mg, Dolutegravir sodium equivalent to dolutegravir 50 mg
  • Dosage: Once a day, without regard for food

Atenef

Atenef is indicated for the use alone as a complete regimen or in combination with other anti-retroviral agents for the treatment of HIV-1 infection in adults

  • Reg. No. 47/20.2.8/0483.
  • Schedule 4
  • Each tablet contains Tenofovir 300 mg, Emtricitabine 200 mg and Efavirenz 600 mg
  • Dosage: Once a day on an empty stomach

Sonke Efavirenz 200

  • Reg. No. A40/20.2.8/0507
  • Schedule 4
  • Each film-coated tablet contains Efavirenz 200 mg
  • Sugar free
  • Dosage: Evening

Sonke Efavirenz 600

  • Reg. No. A40/20.2.8/0508
  • Schedule 4
  • Each capsule contains Efavirenz 200 mg
  • Dosage: Evening

Sonke Lamivudine 150

  • Reg. No. A40/20.2.8/0272
  • Schedule 4
  • Each film-coated tablet contains Lamivudine 150 mg
  • Sugar free
  • Dosage: Morning & Evening

Terms of use | Privacy Statement| Disclaimer | Copyright © 2017 Sonke Pharmaceuticals. All rights Reserved.